As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.
6 Analysts have issued a Pulse Biosciences, Inc. forecast:
6 Analysts have issued a Pulse Biosciences, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -63 -63 |
44%
44%
|
EBIT (Operating Income) EBIT | -64 -64 |
43%
43%
|
Net Profit | -60 -60 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Head office | United States |
CEO | Paul LaViolette |
Employees | 75 |
Founded | 2014 |
Website | www.pulsebiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.